[ET Net News Agency, 28 May 2020] CSPC Pharmaceutical Group Limited (01093) said
"SYHA1805" developed by the group has obtained approval granted by the National Medical
Products Administration of the People's Republic of China to conduct clinical trials in
China.
The product is a new type of small-molecule agonist and currently there is no product of
the same type available in the global market. The clinical indication for this approval is
the treatment of nonalcoholic steatohepatitis (NASH). The pre-clinical studies have shown
that the product has a high selectivity of efficacy targets, can significantly ameliorate
liver fibrosis and has excellent in vivo and in vitro activities as well as good safety,
providing a promising prospect of demonstrating good efficacy in the clinical trials. (RC)